IP Library Granted Patent US 10,874,681
Granted Patent B2
US 10,874,681 · App. 16/174,125 · Granted Dec 29, 2020

Oral lipid supplements for treating pain and fibromyalgia

Inventor: Robert A. Settineri (Irvine, CA)
Assignee: NUTRITIONAL THERAPEUTICS, INC.
A61K31/702A23D9/013A23L29/10A23L29/244A23L33/105A23L33/115A23L33/12A61K9/006A61K9/0056A61K31/05A61K31/122A61K31/16A61K31/375A61K31/385A61K31/522A61K31/593A61K31/66A61K31/661A61K31/683A61K31/685A61K31/7028A61K31/716A61K31/733A61K33/22A61K38/28A61K38/44A61K38/446A61K45/06A61K47/12A61K47/24A61K47/26A61P21/00A61P39/06C12Y111/01006C12Y115/01001A23V2002/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,874,681
App. No.
16/174,125
Granted
Dec 29, 2020
Kind
B2
Abstract

A method of oral delivery of phospholipid/inulin compositions comprising capsules, tablets, chewable wafers or powdered material in a liquid carrier in quantities effective for treating systemic pain from fibromyalgia. The compositions further including effective amounts of caffeine also reduces fatigue and enhances alertness and focus.

Claims (29)

1. A method of treating an individual diagnosed as having fibromyalgia wherein the individual is provided

a) a liquid for drinking, the liquid having a powder dissolved or suspended therein, or

b) an ingestible tablet or capsule the powder, tablet, or capsule comprising a combination of inulin, and phospholipids in therapeutically effective amounts for relieving the symptoms of fibromyalgia, or

c) a chewable wafer comprising:

i) a base composition comprising a combination of inulin, and phospholipids in therapeutically effective amounts for relieving the symptoms of fibromyalgia, and

ii) a carrier for the base composition comprising xylitol, a flavoring agent, stearic acid and/or vegetable stearate, and

wherein the phospholipids comprise about 19-29% phosphatidylcholine (PC), 15-25% phosphatidylethanolamine (PE), 3.5%-10% phosphatidic acid (PA), 10-18% phosphatidylinositol (PI), 2-10% phosphatidylglycerol (PG), 10-20% glycolipids and phosphatidylserine (PS).

2. The method of claim 1 wherein an effective unit dose comprises at least about 1 g of the phospholipids.

3. The method of claim 2 wherein an effective daily dosage is 4 g of the phospholipids, said daily dosage comprising four unit dosages delivered approximately every 6 hours over a 24-hour period.

4. The method of claim 3 wherein the daily dosage is delivered for about 14 days.

5. The method of claim 2 wherein the unit dosage also includes an amount of caffeine effective to reduce fatigue and enhance alertness and/or focus.

6. The method of claim 1 wherein an effective unit dose comprises at least 1.2 g of the phospholipids.

7. The method of claim 6 wherein an effective daily dosage is 4.8 g of the phospholipids, said daily dosage comprising four unit dosages delivered approximately every 6 hours over a 24-hour period.

8. A method of treating an individual diagnosed as having fibromyalgia while also reducing fatigue and enhancing alertness comprising orally delivering to said individual:

a) a liquid having a powder dissolved or suspended therein,

b) an ingestible tablet or capsule,

wherein the powder, the tablet, or the capsule comprises a combination of inulin and phospholipids in therapeutically effective amounts for relieving the symptoms of fibromyalgia and caffeine in therapeutically effective amounts for reducing fatigue and enhancing alertness and/or focus, or

c) a chewable wafer comprising:

i) a base composition comprising a combination of inulin, and phospholipids in therapeutically effective amounts for relieving the symptoms of fibromyalgia,

ii) a carrier for the base composition comprising xylitol, a flavoring agent, stearic acid and/or vegetable stearate, and

iii) caffeine,

wherein the phospholipids comprise phosphatidylcholine, phosphatidylethanolamine, phosphatidic acid, phosphatidylinositol, phosphatidylglycerol, glycolipids and phosphatidylserine.

9. The method of claim 8 wherein an effective unit dose comprises about 1 g of the phospholipids and about 1 gm of caffeine.

10. The method of claim 8 wherein an effective unit dose comprises about 1 g of the phospholipids and about 1.75 gm of caffeine.

11. The method of claim 8 wherein an effective daily dosage is four 1 g dosages of the phospholipids and four 1 g dosages of caffeine, said 1 g dosages delivered approximately every 6 hours in a 24-hour period.

12. The method of claim 8 wherein an effective daily dosage is at least about 4 g of the phospholipids and at least about 4 g of caffeine delivered over a 24-hour period.

13. The method of claim 11 wherein the daily dosage is delivered for about 14 consecutive days.

14. The method of claim 12 wherein the daily dosage is delivered for about 14 consecutive days.

15. The method of claim 8 wherein the phospholipids comprises about 19-29% phosphatidylcholine (PC), 15-25% phosphatidylethanolamine (PE), 3.5%-10% phosphatidic acid (PA), 10-18% phosphatidylinositol (PI), 2-10% phosphatidylglycerol (PG), 10-20% glycolipids and phosphatidylserine (PS).

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 31, 2020
From: ALLERGY RESEARCH GROUP, LLC.
To: NUTRITIONAL THERAPEUTICS, INC.
Reel/Frame 053376/0027 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 29, 2018
From: SETTINERI, ROBERT A.
To: ALLERGY RESEARCH GROUP, LLC
Reel/Frame 047345/0072 →
Continuity (7)
Division 15662212 · Jul 27, 2017
Continuation In Part 15295878 · Oct 17, 2016
Continuation In Part 14815841 · Jul 31, 2015
Continuation In Part 14152938 · Jan 10, 2014
Continuation In Part 13208255 · Aug 11, 2011
Provisional Application 61750991 · Jan 10, 2013
Related Publication 20190060335A1 · Feb 28, 2019